Astrazeneca (AZN) Acquisitions (2009 - 2026)
Astrazeneca (AZN) posted quarterly Acquisitions of $7.6 billion for Q1 2026, up 44.55% year-over-year from $5.2 billion in Q1 2025, and up 126100.0% quarter-over-quarter from -$6.0 million in Q4 2025.
Astrazeneca (AZN) Acquisitions (2009 - 2026) Analysis & Trends
Astrazeneca's Acquisitions history runs 17 years deep, the most recent figure standing at $7.6 billion for Q1 2026.
- In Q1 2026, Acquisitions rose 44.55% year-over-year to $7.6 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 28.92% YoY), while the FY2025 annual figure was -$66.0 million, up 97.62% from the prior year.
- Acquisitions for Q1 2026 stood at $7.6 billion, up from -$6.0 million in the prior quarter.
- The five-year high for Acquisitions was $7.6 billion in Q1 2026, with the low at -$7.1 billion in Q3 2025.
- The 5-year median for Acquisitions is -$97.5 million (2023), against an average of $935.1 million.
- The sharpest annual moves came in 2024 and 2025: Acquisitions plunged 284.13% in 2024, then soared 820.39% in 2025.
- Astrazeneca's Acquisitions stood at -$945.0 million in 2022, then soared by 80.0% to -$189.0 million in 2023, then tumbled by 982.01% to -$2.0 billion in 2024, then surged by 99.71% to -$6.0 million in 2025, then jumped by 126100.0% to $7.6 billion in 2026.
- Business Quant data shows AZN's Acquisitions at $7.6 billion in Q1 2026, -$6.0 million in Q4 2025, and -$7.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.10 Bn | 631.35 Bn | 17.26 Bn | -17.24 Bn |
| 2 | AbbVie | 469.76 Bn | 463.19 Bn | 12.70 Bn | - |
| 3 | Merck | 375.02 Bn | 367.88 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.10 Bn | 295.41 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.62 Bn | 252.72 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.38 Bn | 222.39 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn | 11.21 Bn |
| 8 | Pfizer | 159.63 Bn | 147.93 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.18 Bn | 47.80 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.56 Bn |
| Dec 31, 2025 | -6.00 Mn |
| Sep 30, 2025 | -7.12 Bn |
| Jun 30, 2025 | 1.83 Bn |
| Mar 31, 2025 | 5.23 Bn |
| Jun 30, 2024 | -2.05 Bn |
| Mar 31, 2024 | -726.00 Mn |
| Mar 31, 2023 | -189.00 Mn |
| Jun 30, 2022 | -945.00 Mn |
| Mar 31, 2022 | 5.76 Bn |
| Sep 30, 2021 | -24.83 Bn |
| Mar 31, 2021 | 6.03 Bn |
| Jun 30, 2020 | 1.63 Bn |
| Mar 31, 2020 | 2.55 Bn |
| Dec 31, 2019 | 1.06 Bn |
| Sep 30, 2019 | -1.11 Bn |
| Mar 31, 2019 | 4.14 Bn |
| Sep 30, 2018 | 338.12 Mn |
| Dec 31, 2016 | 1.45 Bn |
| Mar 31, 2016 | 2.50 Bn |